Biosimilarity: The FDA Perspective

· CRC Press
电子书
436
符合条件
评分和评价未经验证  了解详情

关于此电子书

Summary:

The focus of this book is on how the U.S. FDA will approve biosimilar drugs, as learned from recent approvals by the FDA. Understanding the limitations of the statutory limits and non-inferiority testing are presented as tools to obviate patient trials and minimize testing of immunogenicity. An in-depth scientific, mathematical and statistical view of the tools required to establish biosimilarity of biological drugs of different complexity -- a must for every developer of biosimilars.

Features:

First comprehensive analysis based on new guidelines and approval packages of several biosimilars

Presents the first approach to challenge FDA in reducing or eliminating any testing in patients.

Provides a comprehensive understanding of the U.S. statutory requirements vis-a-vis the regulatory guidelines

Provides model CQA and Analytical Similarity testing protocols for cytokines and monoclonal antibodies

Allow creation of a fast-to-market pathway to develop biosimilars

作者简介

Sarfaraz K. Niazi Ph.D, is Adjunct Professor at the faculty of University of Houston as well Chairman and President of Therapeutic Proteins Inc.

为此电子书评分

欢迎向我们提供反馈意见。

如何阅读

智能手机和平板电脑
只要安装 AndroidiPad/iPhone 版的 Google Play 图书应用,不仅应用内容会自动与您的账号同步,还能让您随时随地在线或离线阅览图书。
笔记本电脑和台式机
您可以使用计算机的网络浏览器聆听您在 Google Play 购买的有声读物。
电子阅读器和其他设备
如果要在 Kobo 电子阅读器等电子墨水屏设备上阅读,您需要下载一个文件,并将其传输到相应设备上。若要将文件传输到受支持的电子阅读器上,请按帮助中心内的详细说明操作。